Galderma’s prurigo nodularis trial of nemolizumab meets endpoints

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both primary and all key secondary goals.